$144.38
+0.93 (+0.65%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
76 interventional · 7 observational · 38 with posted results
Held by 24 tracked-famous managers (Point72 Asset Management, L.P., Fundsmith LLP, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, +19 more) · FINRA short interest 3.3 days to cover (settled 2026-07-31) · government filings 180d: 7 congress / 10 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Assessing Gingivitis and Plaque From a Marketed ToothpasteNCT07158112Number of Bleeding SitesRandomized · Triple-masked · Treatment | Phase 4 | Active, not recruiting | Drug: Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice, Sodium monofluorophosphate dentifrice | Gingivitis | 120 | 2025-12-07 | 2025-09-23 |
| Evaluating Gingivitis and Systemic BiomarkersNCT06962956Number Bleeding SitesRandomized · Double-masked · Basic science | Phase 1 | Active, not recruiting | Drug: 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice, 0.454% Stannous Fluoride Dentifrice | Gingivitis | 135 | 2025-10-31 | 2025-06-03 |
| Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.NCT06892834results2026-05-04Number Bleeding SitesRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, Sodium monofluorophosphate dentifrice | Gingivitis | 120 | 2025-06-19actual | 2026-05-04 |
| Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ ModelNCT06140758Mineral DensityRandomized · Triple-masked · Treatment | Not applicable | Completed | Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice, Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice, Toms of Maine 0 ppm Fluoride Dentifrice, Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice, 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice, 1100 ppm (0.454% Stannous fluoride) Dentifrice | Caries | 12 | 2023-12-11actual | 2024-02-29 |
| A Clinical Study to Assess the Gingivitis and Plaque Effects of Various DentifricesNCT06140784Löe-Silness Gingivitis EvaluationRandomized · Triple-masked · Treatment | Not applicable | Completed | Drug: 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice, 0.454% Stannous Fluoride Dentifrice, 0.454% Stannous Fluoride Dentifrice | Gingivitis | 116 | 2023-12-10actual | 2024-03-01 |
| A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Different Etiologies.NCT05619328Neuropathy Total Symptom Score-6 (NTSS-6)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Vitamin B combination tablet, Placebo Tablet | Peripheral Sensory Neuropathy of Different Etiologies | 323 | 2023-11-02actual | 2023-11-28 |
| A Meta-analysis Comparing Toothbrushes on Plaque Removal and Gingival HealthNCT05594004observationalNumber of Bleeding Sites | — | Completed | Device: Oscillating-rotating electric toothbrush, Sonic electric toothbrush, Manual toothbrush | Gingivitis, Dental Plaque | 2,929 | 2022-07-29actual | 2022-10-26 |
| Stannous Fluoride and GingivitisNCT05326373MGINon-randomized · Single-masked · Treatment | Not applicable | Completed | Drug: Stannous fluoride | Gingivitis | 40 | 2022-06-13actual | 2022-06-16 |
| Brief Title: a Clinical Study to Assess GingivitisNCT06659471Number Bleeding SitesRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice | Gingival Diseases | 120 | 2022-06-06actual | 2024-10-26 |
| Overnight Pant Study for Children With Nocturnal EnuresisNCT05178641results2024-10-01Number, Frequency and Severity of Product Related Adverse EventsRandomized · Single-masked · OtherStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Ninjamas Pyjama Pants · Other: Participant's Overnight Current Standard of Care | Nocturnal Enuresis | 32 | 2022-02-28actual | 2024-10-01 |
| A Three Month Bleeding-Model Clinical StudyNCT05916521Löe-Silness Gingivitis EvaluationRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: 0.454% stannous fluoride, 0.76% sodium monofluorophosphate, 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM | Gingivitis | 90 | 2022-02-11actual | 2023-06-23 |
| A Clinical Study to Assess the Gingivitis Effects of Various DentifricesNCT06140771Löe-Silness Gingivitis EvaluationRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: 0.76% Sodium Monofluorophosphate Dentifrice, 1.15% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice, 0.454% Stannous Fluoride Dentifrice | Gingivitis | 115 | 2022-02-06actual | 2023-11-20 |
| Salivary Fluoride ClearanceNCT06735235area under the curve (AUC)Randomized · Double-masked · Basic science | Phase 1 | Completed | Drug: 0 ppm F, 250 ppm F as MFP, 1100 ppm as MFP, 2800 ppm F as MFP | Caries | 27 | 2021-07-29actual | 2024-12-16 |
| Evaluation of the Fluoride Dose Response Using In Situ Caries ModelNCT04763044results2022-07-19Enamel Fluoride Uptake (EFU)Randomized · Double-masked · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: 0 ppm F, 250 ppm F as MFP, 1100 ppm as MFP, 2800 ppm F as MFP, 1100 ppm SnF2 | Caries | 15 | 2021-07-21actual | 2022-07-19 |
| Assessing Effects of a Denture Gel on Gum AbrasionsNCT04913636results2022-06-28Abrasion Assessment (Number)Randomized · Single-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Treatment Gel · Other: Sham Control | Gum Injury | 38 | 2021-06-29actual | 2022-06-28 |
| Measuring Efficacy of an Oral-Irrigator After Three Weeks of UseNCT04899440results2022-08-01MGI-Modified Gingival IndexRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Water Flosser · Other: Control | Gingivitis, Plaque | 30 | 2021-06-24actual | 2022-08-01 |
| Evaluation of Dentifrice Formulations to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind In-Situ Clinical TrialNCT06140745Mineral DensityRandomized · Triple-masked · Treatment | Not applicable | Completed | Drug: 0 ppm Fluoride Dentifrice 1, 1100 ppm NaF Fluoride Dentifrice, 1500 ppm NaMFP Fluoride Dentifrice, 0 ppm Fluoride Dentifrice 2, 0 ppm Fluoride Dentifrice 3 | Caries | 10 | 2021-02-21actual | 2023-11-20 |
| A Bleeding-Model Clinical StudyNCT05916508Löe-Silness Gingivitis EvaluationRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: 0.454% stannous fluoride, 0.76% sodium monofluorophosphate, 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM | Gingivitis | 90 | 2020-11-20actual | 2023-06-23 |
| Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water ControlNCT04189081results2021-05-06Response to "Relieving the Discomfort of Dry Mouth" From the Modified PPAQ I 4- and 6-hours Post-use on Day 1 of TreatmentRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: dry mouth rinse · Other: Water Control | Dry Mouth | 137 | 2020-07-08actual | 2021-05-28 |
| A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth RinseNCT04152642results2021-02-02Product Performance and Attributes (PPAQ I) Question #1: 2-hr at Day 4Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Marketed Dry Mouth Rinse, Experimental Dry Mouth Rinse · Other: Water control | Dry Mouth | 22 | 2019-12-05actual | 2021-02-02 |
| A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal HypersensitivityNCT03965039results2020-10-30Air ChallengeRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Dipotassium oxalate toothpaste · Drug: Stannous fluoride toothpaste, Potassium nitrate toothpaste, Sodium monofluorophosphate toothpaste | Dentin Hypersensitivity | 120 | 2019-10-03actual | 2020-10-30 |
| A Study to Determine the Efficacy of a Denture Adhesive to Seal Out Food Particles From Under the Mandibular Partial DentureNCT05908890Poppy Seed Count Before Treatment ApplicationRandomized · Double-masked · Prevention | Not applicable | Completed | Device: Experimental Denture Adhesive, Fixodent True Feel Denture Adhesive | Partial Denture | 29 | 2019-10-03actual | 2023-06-18 |
| A Clinical Study to Assess the Plaque and Gingivitis Effects of a Stannous Fluoride DentifriceNCT03936569Löe-Silness Gingivitis EvaluationRandomized · Double-masked · Treatment | Phase 4 | Completed | Drug: Marketed Toothpaste, Marketed Cavity Protection Toothpaste | Gingivitis | 90 | 2019-01-25actual | 2023-06-08 |
| Meta-analysis of Stannous Fluoride and the Effects on Gingival HealthNCT03970759observationalNumber of Bleeding Sites | — | Completed | Drug: Stannous Fluoride Dentifrice, Positive control dentifrice, Negative control dentifrice | Gingivitis | 2,890 | 2018-11-30actual | 2019-06-17 |
| Meta-analysis of Stannous Fluoride Dentifrice and the Effects on Dentine HypersensitivityNCT04005417observationalChange from Baseline Air Challenge | — | Completed | Drug: Stannous fluoride dentifrice, Positive control dentifrice, Negative control dentifrice | Dentine Hypersensitivity | 1,036 | 2018-11-30actual | 2019-07-02 |
| Meta-analysis of Stannous Fluoride and the Effects on Enamel ErosionNCT04006470observationalChange from Baseline Surface profilometry | — | Completed | Drug: Stannous fluoride dentifrice, Positive control dentifrice, Negative control dentifrice | Enamel Erosion | 172 | 2018-11-30actual | 2019-07-05 |
| Meta-analysis of Stannous Fluoride and the Effects on Dental PlaqueNCT04006483observationalDental Plaque Scores | — | Completed | Drug: Stannous fluoride dentifrice, Positive control dentifrice, Negative control dentifrice | Dental Plaque | 2,359 | 2018-11-30actual | 2023-11-18 |
| The Effects of Oscillating-Rotating Electric Toothbrushes on Plaque and Gingival HealthNCT04017507observationalNumber of Bleeding Sites | — | Completed | Device: Oscillating-rotating electric toothbrush, Side-to-side electric toothbrush, Manual toothbrush | Gingivitis, Plaque | 2,145 | 2018-11-30actual | 2019-08-15 |
| In-use Cross-over Study of Two Different Menstrual CupsNCT05411796Vaginal erythemaRandomized · Double-masked · Other | Not applicable | Completed | Device: Tampax menstrual cup, Other menstrual cup | Menstruation | 65 | 2018-11-14actual | 2022-06-09 |
| A Clinical Comparison of an Experimental Power Brush Compared to a Manual ToothbrushNCT03624647Modified Gingival IndexRandomized · Single-masked · Treatment | Not applicable | Completed | Device: Power toothbrush, Manual toothbrush | Gingivitis, Dental Plaque | 110 | 2018-09-14actual | 2018-09-27 |
| 8-Week Atopic Dermatitis (AD) Treatment StudyNCT03386032results2020-12-17Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic DermatitisRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Investigational OTC Cream, 0.05% Desonide · Other: Placebo Cream | Atopic Dermatitis Eczema | 65 | 2018-08-18actual | 2020-12-17 |
| In-use Study of Four Different TamponsNCT03478371results2019-08-26Tolerance of Tampon Wear Via Physician Assessment of Vaginal HealthRandomized · Double-masked · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: tampon D, tampon M, tampon T, tampon V | Menstruation | 94 | 2018-07-18actual | 2019-08-26 |
| Evaluate Dental Plaque Benefit of a Preventive Treatment GelNCT03546491results2019-09-04Mean Turesky Modified Quigley-Hein Index at Day 4Randomized · Single-masked · PreventionStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Preventive Gel, Marketed Control | Dental Plaque | 32 | 2018-06-22actual | 2019-09-04 |
| A Clinical Study to Assess the Effects of a Stannous Fluoride Dentifrice on Plaque and GingivitisNCT03936556Löe-Silness Gingivitis EvaluationRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Marketed toothpaste, Marketed Cavity Protection Toothpaste | Gingivitis | 84 | 2018-06-03actual | 2019-12-04 |
| Analysis of Stannous Fluoride in GCF and Subgingival PlaqueNCT03296657Amount of tin in GCF sampleOpen-label · Basic science | Not applicable | Completed | Drug: stannous fluoride | Subgingival Plaque, GCF | 20 | 2017-09-22actual | 2017-11-06 |
| A Follow-Up Survey of Oral Hygiene and Health Outcomes for Women Previously Enrolled in "OHMOM"NCT02922010observationalLöe-Silness Gingivitis Index | — | Completed | — | Gingivitis | 35 | 2017-06-30actual | 2017-09-19 |
| Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal HypersensitivityNCT02613117results2020-09-22How Satisfied Were Participants With Treatment?Non-randomized · Open-label · Treatment | Not applicable | Completed | Device: Potassium Oxalate Gel, Potassium Oxalate Liquid · Drug: Stannous fluoride paste | Dentinal Hypersensitivity | 104 | Jun 2016actual | 2020-09-22 |
| A Study to Evaluate Sampling Methods for Subgingival PlaqueNCT02841839Subgingival plaqueOpen-label · Basic science | Not applicable | Completed | Drug: Stannous Fluoride | Subgingival Plaque | 20 | Jun 2016actual | 2023-11-15 |
| A Study to Evaluate Oral Malodor and Other Outcomes Following The Use of Two-Step Toothpaste Oral HygieneNCT02613130Breath odorRandomized · Double-masked · Treatment | Not applicable | Completed | Drug: Stannous fluoride toothpaste, Potassium nitrate toothpaste | Oral Malodor | 60 | Dec 2015actual | 2017-10-03 |
| A Pilot Study to Evaluate a Molecular Method for PlaqueNCT02574221plaque scoresRandomized · Double-masked · Basic science | Not applicable | Completed | Drug: stannous fluoride toothpaste, cavity protection toothpaste | Plaque, Gingivitis | 60 | Oct 2015actual | 2017-10-06 |
| A Clinical Study to Determine the Safety and Effectiveness of Dentinal Hypersensitivity Treatment With Two Different ToothbrushesNCT02513212results2020-08-31Change From Baseline Air ChallengeRandomized · Single-masked · Treatment | Not applicable | Completed | Device: Potassium Oxalate, Manual toothbrush, Power toothbrush · Drug: Stannous fluoride paste | Dentin Sensitivity | 24 | Sep 2015actual | 2020-08-31 |
| A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular DentifriceNCT02543060plaque scoresRandomized · Double-masked · Basic science | Not applicable | Completed | Drug: stannous fluoride toothpaste, cavity protection toothpaste | Plaque, Gingivitis | 60 | Aug 2015actual | 2017-10-06 |
| Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental ProphylaxisNCT02481557results2019-05-29Change From Baseline Air ChallengeRandomized · Open-label · Treatment | Not applicable | Completed | Device: Oxalate Salt Solution | Dentin Sensitivity | 36 | Jun 2015actual | 2019-06-11 |
| A Pilot Study to Assess Nominal Versus Controlled Stimuli on Dentinal HypersensitivityNCT02406573results2019-08-28Change From Baseline for Visual Analog Scale - Cold WaterOpen-label · Treatment | Not applicable | Completed | Device: Crest® Sensi-Stop™ Strips | Dentin Sensitivity | 30 | Apr 2015actual | 2019-08-28 |
| A Pilot Clinical Study to Evaluate the Safety and Efficacy of Marketed Oxalate Strips Compared to a Marketed Safety PenNCT02384044results2019-05-21Change From Baseline Visual Analog ScaleRandomized · Open-label · Treatment | Not applicable | Completed | Device: Crest® Sensi-Stop™ Strips, Colgate® Sensitivity Relief Pen | Dentin Sensitivity | 30 | Mar 2015actual | 2019-06-25 |
| A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary IncontinenceNCT02160314results2016-02-15Treatment-emergent Serious Adverse EventRandomized · Single-masked · Treatment | Not applicable | Completed | Device: pessary, Absorbent pad | Stress Urinary Incontinence | 224 | Jan 2015actual | 2016-02-15 |
| Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional SleeplessnessNCT02578186results2017-03-15Mean Latency to Persistent SleepRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Diphenhydramine Hydrochloride, Placebo | Occasional Sleeplessness | 33 | Dec 2014actual | 2017-03-15 |
| A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal HypersensitivityNCT02293044results2019-05-21Change From Baseline Cold Water ChallengeOpen-label · Treatment | Not applicable | Completed | Device: Crest® Sensi-Stop™ Strips | Dentin Sensitivity | 15 | Nov 2014actual | 2019-06-25 |
| A Clinical Study of Two Dentinal Hypersensitivity Treatments Used With Normal Oral HygieneNCT02221349results2020-09-09Change From Baseline Air ChallengeRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Potassium oxalate · Drug: Sodium fluoride paste, Stannous fluoride paste | Dentin Sensitivity | 30 | Oct 2014actual | 2020-09-09 |
| A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)NCT02131311results2016-03-24Percentage of Responders for Pad Weight Gain or SUI EpisodesOpen-label · Treatment | Not applicable | Completed | Device: disposable, single-use pessary | Stress Urinary Incontinence (SUI) | 145 | Sep 2014actual | 2016-03-24 |
| Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental HypersensitivityNCT02152826results2020-09-18Change From Baseline for Air ChallengeRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Potassium oxalate | Dentin Sensitivity | 80 | Sep 2014actual | 2020-09-18 |
| Effectiveness of Two Water-Based Potassium Oxalate DesensitizersNCT02192307results2019-11-05Change From Baseline Air ChallengeRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Potassium oxalate | Dentin Sensitivity | 60 | Sep 2014actual | 2019-11-05 |
| Evaluation of the Safety and Efficacy of an Oxalate Gel or Negative Control on Dentinal HypersensitivityNCT02189382results2018-08-20Change From Baseline Air ChallengeRandomized · Single-masked · Treatment | Not applicable | Completed | Device: Potassium Oxalate · Other: Water | Dentin Sensitivity | 70 | Jul 2014actual | 2018-08-20 |
| Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)NCT01549587results2020-10-19Change From Baseline in Löe-Silness Gingivitis IndexRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Drug: 0.243% sodium fluoride, 0.454% stannous fluoride, 0.07% Cetylpyridinium chloride · Device: toothbrush, dental floss, toothbrush, dental floss | Gingivitis, Pregnancy | 746 | Feb 2014actual | 2023-04-21 |
| A Clinical Study to Compare Professional Treatments for Dentinal HypersensitivityNCT03405259results2019-06-17Change From Baseline Air ChallengeRandomized · Single-masked · Treatment | Not applicable | Completed | Device: Super Seal® Desensitizer, Acclean® Fluoride Varnish | Dentinal Hypersensitivity | 22 | 2013-09-13actual | 2019-06-17 |
| A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary IncontinenceNCT01762345results2016-03-24Change in Pad Weight GainOpen-label · Treatment | Not applicable | Completed | Device: pessary (disposable intra-vaginal device) | Stress Urinary Incontinence | 148 | Jul 2013actual | 2016-03-24 |
| Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting GlucoseNCT01549600fasting serum glucoseRandomized · Single-masked · Basic science | Not applicable | Completed | Dietary supplement: psyllium, Microcrystalline Cellulose | Impaired Fasting Glucose | 18 | May 2013actual | 2014-10-28 |
| Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy VolunteersNCT01809925satiety (VAS Hunger 3-day average)Randomized · Triple-masked · Basic science | Not applicable | Completed | Dietary supplement: psyllium fiber 6.8g, placebo | Hunger | 45 | Apr 2013actual | 2014-10-28 |
| A Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene ProductsNCT02401360GingivitisRandomized · Single-masked · Treatment | Not applicable | Completed | Drug: China Crest® Pro-health 7 Complete Toothpaste, China Crest® Cavity Protection Toothpaste | Dental Plaque, Dental Gingivitis | 106 | Apr 2013actual | 2017-10-06 |
| A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment MethodsNCT07211061Bleeding (GBI)Randomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, Cetylpyridinium Chloride (CPC) · Device: electric toothbrush, manual toothbrush | Gingivitis | 69 | 2011-11-10actual | 2025-10-07 |
| Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and BloatingNCT01099696The change in abdominal discomfort and bloatingRandomized · Triple-masked · Treatment | Not applicable | Completed | Dietary supplement: B. infantis 35624, placebo | Abdominal Discomfort, Bloating | 302 | Oct 2010actual | 2012-12-20 |
| A Controlled Clinical Study to Determine the Gingivitis Benefit of FlossingNCT00964860results2012-10-31Mean Interproximal Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing GroupRandomized · Single-masked · Treatment | Phase 3 | Completed | Device: Glide dental floss | Gingivitis | 60 | Aug 2009actual | 2012-10-31 |
| Study Evaluating the Pharmacokinetics of Doxylamine Succinate in ChildrenNCT00796315results2013-01-25AUC of DoxylamineOpen-label | Phase 1 | Completed | Drug: Doxylamine Succinate USP | Allergic Rhinitis, Upper Respiratory Infection | 41 | Jun 2009actual | 2013-02-04 |
| Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid SuppressionNCT00903448results2010-11-22Mean Percent Time That Gastric pH > 4.0 on Day 5Randomized · Triple-masked · Basic science | Phase 4 | Completed | Drug: Prilosec OTC (omeprazole-magnesium), Prevacid | Healthy | 40 | Jun 2009actual | 2010-12-31 |
| Study to Evaluate the Effects of Psyllium on Blood GlucoseNCT00888602to evaluate the effect of 2 dosing levels of psyllium on glucose in blood when taken prior to a meal vs. a meal aloneRandomized · Open-label · Basic science | Not applicable | Completed | Dietary supplement: 3.4 g psyllium, 6.8 g psyllium, 6.8 g psyllium · Other: Meal | Healthy Men | 49 | May 2009actual | 2012-12-20 |
| Weight Loss in Pre-diabetic, Obese WomenNCT00686816weight lossRandomized · Double-masked · Treatment | Phase 2 | Completed | Dietary supplement: Low calorie diet, Olestra | Obesity | 80 | Feb 2009actual | 2009-10-16 |
| A Controlled Clinical Study to Determine the Gingivitis Benefit of FlossingNCT00855933results2013-02-08Whole Mouth Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group [30 Days] Units on the MGI ScaleRandomized · Single-masked · Treatment | Phase 4 | Completed | Device: Experimental Floss | Gingivitis | 60 | Feb 2009actual | 2013-02-08 |
| Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid SuppressionNCT00808769results2011-04-27The Mean Percent Time Gastric pH > 4.0 on Day 1Randomized · Single-masked | Phase 4 | Completed | Drug: Zegerid®, Prilosec OTC® | Normal Healthy Subject Population | 30 | Dec 2008actual | 2015-06-01 |
| Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy Study 2NCT00780286Area under the curve for volume of investigational device retained in the oral cavity.Randomized · Open-label · Treatment | Phase 1 | Completed | Device: Polymer based lubricating liquid, Moi-Stir | Healthy Subjects | 32 | Oct 2008actual | 2019-04-02 |
| Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic ConstipationNCT00501241Total number of spontaneous bowel movements during the first 7 days after randomizationRandomized · Quadruple-masked · Treatment | Phase 2 | Terminated | Drug: ATI-7505, ATI-7505, ATI-7505, ATI-7505, ATI-7505 | Chronic Constipation | 214 | Jul 2008actual | 2009-06-17 |
| A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress SyndromeNCT00630370Efficacy of 3 oral dosing regimens of ATI 7505 vs. placebo in patients with PDS.Randomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Placebo, 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505 | Post Prandial Distress Syndrome | 6 | Jul 2008actual | 2009-06-17 |
| Evaluate Retention of an Orally Administered Device Using Gamma ScintigraphyNCT00754091Area under the curve for the percent of the mucoadhesive liquid retained in the oropharynxOpen-label · Treatment | Phase 1 | Completed | Device: Polymer based lubricating liquid | Healthy Subjects | 16 | Jun 2008actual | 2019-03-26 |
| A Study of the Effects of Probiotics in Children Grades 1-3NCT00635388Number of healthy days.Randomized · Quadruple-masked | Not applicable | Completed | Other: Placebo, Lactobacillus (Probiotic 1), Lactobacillus and Bifidobacterium (Probiotic 2) | Healthy | 360 | May 2008actual | 2009-10-16 |
| Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving MethotrexateNCT00369928results2011-09-08Proportion of Patients Meeting American College of Rheumatology 20 Response Criteria (ACR20) at 12weeksRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PG-760564, Placebo dose, PG-760564 | Rheumatoid Arthritis | 254 | Jan 2008actual | 2011-09-08 |
| Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)NCT00091637Reduction of all causes of mortalityRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Pexelizumab, Placebo infusion | Acute Myocardial Infarction | 5,745 | May 2007actual | 2023-11-18 |
| Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 DaysNCT00791388results2011-11-04AUCτ Over a Dosing Interval (τ = 12 Hours) on Day 14Randomized · Double-masked | Phase 1 | Completed | Drug: Placebo, PG-760564, PG-760564, PG-760564, PG-760564 | Healthy | 45 | Jan 2006actual | 2011-11-04 |
| Study to Evaluate Potential Food EffectsNCT00791817results2011-09-07CmaxRandomized · Open-label | Phase 1 | Completed | Drug: PG-760564, PG-760564 | Healthy | 10 | Jan 2006actual | 2011-09-07 |
| Study of Oral PG-116800 Following a Heart AttackNCT00067236results2011-11-04Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi in mL/m2) at Day 90 Post Myocardial Infarction (MI)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PG-116800 (given as PG-530742), Placebo tablet | Myocardial Infarction, Heart Failure, Heart Enlargement | 253 | Dec 2004actual | 2011-11-04 |
| Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel SyndromeNCT00135031The primary efficacy variable was the abdominal pain scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bifidobacterium infantis 35624 | Irritable Bowel Syndrome | 362 | Sep 2004actual | 2011-06-15 |
| Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee OsteoarthritisNCT00041756results2011-11-08Change in Minimum Joint Space Width in the Medial Compartment of the Tibiofemoral Joint of the Signal Knee After 1 Year of TreatmentRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: PG-530742, Placebo, 50 mg PG-530742, 100 mg PG-530742, 200 mg PG-530742 | Osteoarthritis, Knee | 395 | Feb 2004actual | 2011-11-08 |
| A Study to Assess the Ingestion of Dentifrice by ChildrenNCT02409836Level of dentifrice ingested and used by various age groups of children.Randomized · Open-label | Not applicable | Completed | Drug: Marketed Dentifrice, Marketed Flavored Dentifrice, Marketed Flavored Dentifrice | Healthy Individuals | 90 | Jul 1993actual | 2015-04-07 |
| Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM SubjectsNCT01582282results2012-11-02Change From Baseline in Fasting GlucoseRandomized · Double-masked · Basic science | Phase 4 | Terminatedsponsor's stated reason: due to slow enrollment | Dietary supplement: placebo, 3.4 g psyllium BID, 6.8g psyllium BID | Non-Insulin-dependent Diabetes Mellitus | 37 | Jan 1990actual | 2012-11-15 |
| The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected PatientsNCT00002431Treatment | Not applicable | Completed | Drug: Chlorhexidine gluconate | Candidiasis, Oral, HIV Infections | — | — | 2005-06-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19